The COSENTYX® (secukinumab) Joint Decision program is an immersive program in which you assume the role of the healthcare professional and guide simulated interactions with 2 hypothetical patients, Mark and Melanie. Their symptoms tell a story. Developed and offered by Novartis Pharmaceuticals Corporation.
Non-CME
